Last updated on December 2017

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Migraine | Migraine (Pediatric)
  • Age: Between 6 - 17 Years
  • Gender: Male or Female

Body weight of 15 to 45 kg at Visit 1.


Agree not to post any personal medical data related to the study or information related to the study on any website or social media site (Facebook, Twitter, Snapchat, Instagram, Google+, etc.) until notification that the trial has completed.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.